Search the Studies

65 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
11-C-0034DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History StudyParticipants currently recruited/enrolled0-125 YearsNCI Ovarian Cyst
02-DK-0022Long-Term Efficacy of Leptin Replacement in Treatment of LipodystrophyCompleted Study; data analyses ongoing1-125 YearsNIDDKOvarian Cyst
001099-CA Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-Fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors thatParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
001004-CA Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon Oncosignature (R) StatusParticipants currently recruited/enrolled18-120 YearsNCI Ovarian
000954-CA Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients with Advanced Mesothelin-Expressing CancerParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
000783-CPhase I/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 with PD-1 Inhibitor, Nivolumab with or without CTLA-4 Inhibitor, Ipilumumab in Solid TumorsParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
000715-CHBiorepository in Participants Who Undergo OTC for Gonadotoxic TherapyParticipants currently recruited/enrolled4-35 YearsNICHDOvarian
000567-CPhase 1 Trial of Gemcitabine Combined with the BAY 1895344 ATR Inhibitor with Expansion Cohorts in Advanced Pancreatic and Ovarian CancerParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
000484-CRandomized Phase II Trial of Durvalumab (D) plus Olaparib (O) and Cediranib (C: DOC) Compared to OC or DC or Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer with Prior BevacizumabParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
000237-CPhase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis from Colorectal, Appendiceal, Small Bowel, Gastric, Ovarian, or Other Gynecologic Primary CancerParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
000106-CHGonadal Tissue Freezing for Fertility Preservation in Individuals at risk for Ovarian Dysfunction and Premature Ovarian InsufficiencyParticipants currently recruited/enrolled4-21 YearsNICHDOvarian
21-I-0029Natural history, epidemiology and pathogenesis of severe HPV-related diseases (Neptune)Participants currently recruited/enrolled3-125 YearsNIAIDCyst
21-C-0012Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma HistologiesParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
20-C-0098A Phase 1/2, Open Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects with Advanced or Metastatic Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
20-C-0020Ex-Vivo Trial of En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope DeviceParticipants currently recruited/enrolled18-125 YearsNCI Cyst
20-C-0013Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell CancersNo longer recruiting/follow-up only18-125 YearsNCI Ovarian
19-H-0100Best Noninvasive Predictor of Renal Function in Assessing Adult Sickle NephropathyCompleted Study; data analyses ongoing18-125 YearsNHLBICyst
19-C-0143A Phase II Study Using the Administration of Autologous T-Cells Engineered using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic CancerParticipants currently recruited/enrolled18-70 YearsNCI Ovarian
19-C-0135Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine TumorsParticipants currently recruited/enrolled12-125 YearsNCI Cyst
19-C-0117A Phase 1 / 2 Single Arm Open-label Clinical Trial of Gavocabtagene Autoleucel (gavo-cel) in Patients with Advanced Mesothelin Expressing CancerParticipants currently recruited/enrolled18-120 YearsNCI Ovarian
19-C-0025Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic MalignanciesEnrolling by Invitation18-125 YearsNCI Ovarian
18-C-0143A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior ChemotherapyCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
18-C-0049A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients with Metastatic CancerParticipants currently recruited/enrolled18-72 YearsNCI Ovarian
17-C-0157A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (oportuzumab monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with Bacillus Calmette-Gu(SqrRoot)(Copyright)rin (BCG)Participants currently recruited/enrolled18-125 YearsNCI Cyst
17-C-0100Collection of Malignant Ascites, Pleural Fluid and Blood from Patients with Solid TumorsNo longer recruiting/follow-up only18-125 YearsNCI Ovarian
17-C-0011Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron (Peginterferon alfa-2b) and Actimmune (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
16-C-0131A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing CancersParticipants currently recruited/enrolled18-70 YearsNCI Ovarian
16-C-0128A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
16-C-0088A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary PeritoneaCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
16-C-0073A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian CancerCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
15-DK-0108Natural History of Noncirrhotic Portal HypertensionParticipants currently recruited/enrolled12-125 YearsNIDDKCyst
15-C-0150A Phase I/II Trial of Topotecan with VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell CancersNo longer recruiting/follow-up only18-125 YearsNCI Ovarian
15-C-0145Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination with Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
14-C-0156A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian CancerCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
14-C-0056Collection of Blood from Patients with Ovarian, Primary Peritoneal or Fallopian Tube CancerCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
14-C-0036A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination with PANVAC[TM] Versus BCG Given Alone in Adults with High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 ICompleted Study; data analyses ongoing18-125 YearsNCI Cyst
14-C-0015Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA MutationsCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
13-C-0202Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing CancersParticipants currently recruited/enrolled2-125 YearsNCI Ovarian
13-C-0175A Phase II Protocol for Subjects with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radio-sensitizing Chemotherapy following a Thorough Transurethral Surgical Re-StagingCompleted Study; data analyses ongoing18-125 YearsNCI Cyst
13-C-0131Inpatient Hospice with Procurement of Tissue on Expiration in Thoracic Malignancies, Bladder Cancer, Ovarian Cancer, Epithelial Cancer and Patients Treated with an Adoptive Cellular TherapyParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
13-C-0118A Phase I/II Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and LymphomasParticipants currently recruited/enrolled18-125 YearsNCI Ovarian
12-C-0205A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
12-C-0081Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast CancerNo longer recruiting/follow-up only18-125 YearsNCI Ovarian
11-C-0242Collection of Blood from Patients with Cancer, Other Tumors, or Tumor Predisposition Syndromes for Analysis of Genetic Differences in Drug DispositionParticipants currently recruited/enrolled3-125 YearsNCI Ovarian
11-C-0140A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid TumorsCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
11-C-0061Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid TumorsNo longer recruiting/follow-up only18-125 YearsNCI Ovarian
11-C-0033Extended Follow-up of High Ovarian Cancer Risk Cohort from 02C0268 (GOG-199)Completed Study; data analyses ongoing18-100 YearsNCI Ovarian
10-N-0143A Prospective Natural History Study of Patients with SyringomyeliaNo longer recruiting/follow-up only18-125 YearsNINDSCyst
10-CC-0149Comparing Expectorated and Induced Sputum and Pharyngeal Swabs for Cultures, AFB Smears, and Cytokines in Pulmonary Nontuberculous Mycobacterial InfectionCompleted Study; data analyses ongoing18-80 YearsCC Cyst
10-C-0166A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of PembrolizumabParticipants currently recruited/enrolled18-72 YearsNCI Ovarian
09-H-0172Natural History of BronchiectasisParticipants currently recruited/enrolled5-125 YearsNHLBICyst
06-H-0217Genetic Disorders of Mucociliary ClearanceCompleted Study; data analyses ongoing2-65 YearsNHLBICyst
04-C-0232A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of RelapseCompleted Study; data analyses ongoing18-125 YearsNCI Ovarian
02-C-0268Prospective Study of Prophylactic Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian CancerCompleted Study; data analyses ongoing19-100 YearsNCI Ovarian
02-C-0212Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian CancerCompleted Study; data analyses ongoing18-100 YearsNCI Ovarian
02-C-0159Birt-Hogg-Dub(SqrRoot)(Copyright) Syndrome: Characterization of the FLCN Disease Gene and Predisposition to Renal Cancer, Cutaneous Fibrofolliculoma and Pulmonary CystsParticipants currently recruited/enrolled2-125 YearsNCI Cyst
01-I-0202Natural History, Genetics, Phenotype, and Treatment of Mycobacterial InfectionsParticipants currently recruited/enrolled0-100 YearsNIAIDCyst
01-C-0009Breast Imaging Screening Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-up StudyCompleted Study; data analyses ongoing18-100 YearsNCI Ovarian
00-N-0140A Prospective Natural History Study of VHL Patients with CNS HemangioblastomasNo longer recruiting/follow-up only8-75 YearsNINDSCyst
00-N-0089Genetic Analysis of the Chiari I MalformationCompleted Study; data analyses ongoing1-125 YearsNINDSCyst
96-H-0100Role of Genetic Factors in the Pathogenesis of Lung DiseaseParticipants currently recruited/enrolled2-90 YearsNHLBICyst
96-C-0071Follow-up for Patients Previously Enrolled on the Center for Cancer Research ProtocolsNo longer recruiting/follow-up only0-125 YearsNCI Ovarian
87-DK-0029Diagnosis and Treatment of Patients with Cystic FibrosisParticipants currently recruited/enrolled4-125 YearsNIDDKCyst
85-I-0127Natural History of Treated Neurocysticercosis and Long-Term OutcomesParticipants currently recruited/enrolled3-99 YearsNIAIDCyst
78-HG-0093Use of Cysteamine in the Treatment of CystinosisParticipants currently recruited/enrolled0-125 YearsNHGRICyst
10 Center Drive,Bethesda, MD 20892 | Directions
Privacy Statement | Accessibility | Plain Language | FOIA | Disclaimer
Clinical Center | National Institutes of Health | HHS Vulnerability Disclosure | U.S. Department of Health and Human Services | USA.gov
NIH…Turning Discovery Into Health®